Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy amid a year of sharp share price gains.
On June 9, 2026, Director Robert Mashal reported the acquisition of 25,000 shares of Nuvation Bio (NYSE:NUVB) through an open-market transaction, as disclosed in this SEC Form 4 filing
Transaction summary Transaction value based on SEC Form 4 reported price ($4.73). Key questions – How does the size of this purchase compare with Mashal’s historical trading activity? This 25,000-share purchase is below Mashal’s prior largest transactions (100,000 shares in October 2024 and April 2025), but falls within his typical event range, as the historical 75th percentile for all events is 43,750 shares. – What is the effect on Mashal’s overall exposure to Nuvation Bio after this transaction?
Following this acquisition, Mashal’s direct holdings remain at zero, while his indirect stake via a trust rises to 225,000 shares, maintaining meaningful exposure to the company’s equity. – Is there any indication of options, administrative trades, or derivative-related activity in this transaction? No derivative securities or options were involved; the transaction was a straightforward open-market purchase attributed entirely to indirect trust ownership. – How does the market context frame this transaction? On the trade date, Nuvation Bio shares closed at $4.93, up 96% over the same date in 2025, indicating the purchase was executed during a period of strong share price appreciation as of June 9, 2026.